within Pharmacolibrary.Drugs.ATC.B;

model B01AC07
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.37,
    Cl             = 0.002,
    adminDuration  = 600,
    adminMass      = 75 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02333333333333333,
    Tlag           = 600,            
    Vdp             = 0.0016,
    k12             = 150,
    k21             = 150
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B01AC07</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Dipyridamole is an antiplatelet agent that inhibits the uptake of adenosine into platelets, endothelial cells, and erythrocytes, thereby increasing local concentrations of adenosine, which leads to platelet inhibition and vasodilation. It is commonly used for prevention of thromboembolic events and as an adjunct to oral anticoagulation in patients with prosthetic heart valves. It is also used in conjunction with aspirin for secondary prevention of stroke. Dipyridamole is an approved drug and remains in clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics after oral administration of 75 mg dipyridamole tablets in healthy adult volunteers (both sexes), fasting conditions.</p><h4>References</h4><ol><li><p>Nielsen-Kudsk, F, &amp; Pedersen, AK (1979). Pharmacokinetics of dipyridamole. <i>Acta pharmacologica et toxicologica</i> 44(5) 391–399. DOI:<a href=&quot;https://doi.org/10.1111/j.1600-0773.1979.tb02350.x&quot;>10.1111/j.1600-0773.1979.tb02350.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/474151/&quot;>https://pubmed.ncbi.nlm.nih.gov/474151</a></p></li><li><p>Hervey, PS, &amp; Goa, KL (1999). Extended-release dipyridamole/aspirin. <i>Drugs</i> 58(3) 469–477. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199958030-00007&quot;>10.2165/00003495-199958030-00007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10493274/&quot;>https://pubmed.ncbi.nlm.nih.gov/10493274</a></p></li><li><p>Dresse, A, et al., &amp; Heinzel, G (1982). Pharmacokinetics of oral dipyridamole (Persantine) and its effect on platelet adenosine uptake in man. <i>European journal of clinical pharmacology</i> 23(3) 229–234. DOI:<a href=&quot;https://doi.org/10.1007/BF00547559&quot;>10.1007/BF00547559</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6756935/&quot;>https://pubmed.ncbi.nlm.nih.gov/6756935</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B01AC07;
